Charles S. Berkman

2021 - Ligand Pharmaceuticals

In 2021, Charles S. Berkman earned a total compensation of $3M as Senior Vice President and General Counsel at Ligand Pharmaceuticals, a 53% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$203,257
Option Awards$649,308
Salary$451,682
Stock Awards$1,665,811
Other$10,890
Total$2,980,948

Berkman received $1.7M in stock awards, accounting for 56% of the total pay in 2021.

Berkman also received $203.3K in non-equity incentive plan, $649.3K in option awards, $451.7K in salary and $10.9K in other compensation.

Rankings

In 2021, Charles S. Berkman's compensation ranked 4,459th out of 12,412 executives tracked by ExecPay. In other words, Berkman earned more than 64.1% of executives.

ClassificationRankingPercentile
All
4,459
out of 12,412
64th
Division
Manufacturing
1,833
out of 5,498
67th
Major group
Chemicals And Allied Products
762
out of 2,374
68th
Industry group
Drugs
679
out of 2,095
68th
Industry
Pharmaceutical Preparations
484
out of 1,542
69th
Source: SEC filing on April 22, 2022.

Berkman's colleagues

We found three more compensation records of executives who worked with Charles S. Berkman at Ligand Pharmaceuticals in 2021.

2021

John Higgins

Ligand Pharmaceuticals

Chief Executive Officer

2021

Matthew Korenberg

Ligand Pharmaceuticals

Chief Financial Officer

2021

Matthew Foehr

Ligand Pharmaceuticals

Chief Operating Officer

News

You may also like